about
Liver involvement in subjects with rheumatic diseaseHepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseWhat is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?An Australian audit of vaccination status in children and adolescents with inflammatory bowel diseasePreventing infective complications in inflammatory bowel disease.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentHepatitis B vaccination in patients with inflammatory bowel disease.Network-based study reveals potential infection pathways of hepatitis-C leading to various diseasesPrevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region.Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel diseaseSinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitisVaccines and recommendations for their use in inflammatory bowel disease.Role of the Nrf2-ARE pathway in liver diseasesVaccinating Patients With Inflammatory Bowel Disease.Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxisApproach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease.Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease.Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues.The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines.Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination.Protective effects of Danshensu on liver injury induced by omethoate in rats.Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B.Improving care for inflammatory bowel disease patients infected with hepatitis B virus.Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.Profile of infliximab in the treatment of pediatric Crohn's disease.Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication).
P2860
Q22000839-7A5DF76C-D914-46FA-A226-3EE5596A1965Q26827444-F027DEC9-ECB1-4515-8EAB-459DE289F3B2Q27687191-51603686-AEC2-4585-81EC-5FFFFE12B710Q33974382-48F8EE55-C05E-4763-8B1E-64A867C71B3CQ34008766-F4AA9728-092B-4BB2-8544-C674AFBD1697Q34073191-C38078A0-2DC0-4BE8-AD51-E2DAF5FB71EAQ34467285-8780EA54-11D1-4496-B282-A0C13D7C876FQ35151509-E18F74AF-97E0-466F-897F-BD7E88D3D68FQ36109460-520B1893-D782-4718-A9D2-A6B622DC7336Q36193710-9C94ECE6-07F8-4725-8A87-C4B41E6A69A6Q36673558-06D41D36-272C-4F81-BFDF-6BA037D1701AQ36699251-EB05FD97-A179-420E-AD69-9003D38E2707Q36879950-19FE8E07-55DF-4BE4-8844-A2DC3A15A783Q37421543-46D8E6C8-BB1F-4970-8890-A77415AD9DB7Q37892162-45153DF4-1507-4CB6-8814-90154DC65391Q38094015-3D5BD3DC-1F49-48C2-8C35-AB5B5BD5FAB5Q38235053-10B95A9F-7C7E-4FAB-82BE-158AA372823BQ38372800-462DDADC-1459-49A1-944F-6002393884D4Q38539281-B839DB1D-C16B-44FB-AB19-6873F65DECE4Q40327479-B6948812-FE1E-4B9C-B419-AB0A4FEE3F93Q40946497-74715CBE-A5A6-400D-9789-ACC364C56F7DQ42197661-445ADEAC-3559-4C96-BB39-9E079C11E34BQ42906718-4BE483FC-9FAD-43FC-AFBE-402464496CC5Q42978890-15EC91BD-FB73-4FB0-9271-F9DD4100DC53Q44464843-7BC7576A-E453-4858-B19D-7B4341FD547DQ45352920-6238636C-8A00-4D43-923A-5EAF8B255C67Q45358091-2A21ABA6-4602-4B6D-94C0-856EB5FB0028Q49165025-E42337DA-C524-4A91-8BD2-F4768439788BQ54216562-69997C3C-06F3-4F0F-B898-1D5488DFED85
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Viral hepatitis and inflammatory bowel disease.
@en
Viral hepatitis and inflammatory bowel disease.
@nl
type
label
Viral hepatitis and inflammatory bowel disease.
@en
Viral hepatitis and inflammatory bowel disease.
@nl
prefLabel
Viral hepatitis and inflammatory bowel disease.
@en
Viral hepatitis and inflammatory bowel disease.
@nl
P2093
P2860
P356
P1476
Viral hepatitis and inflammatory bowel disease.
@en
P2093
Fernando Velayos
Jason K Hou
Norah Terrault
Uma Mahadevan
P2860
P304
P356
10.1002/IBD.21284
P577
2010-06-01T00:00:00Z